ArticleHIV medicine2022
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV.
Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- 'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.The Journal of antimicrobial chemotherapy · 2026Observational
- Adverse Events Among People Living With HIV Receiving Dolutegravir-Based Regimens: Findings From a 6-Month Active Pharmacovigilance Study in Uganda.Open forum infectious diseases · 2026Article
- Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional study.BMC medicine · 2025Article
- Evaluation of Insulin Resistance Markers for Diagnosing Moderate to Severe Hepatic Steatosis in Patients With Human Immunodeficiency Virus Using Transient Elastography.Open forum infectious diseases · 2025Article
- Metabolic syndrome among a Ghanaian cohort living with HIV initiated on dolutegravir in a real-world setting: a prospective study.BMJ open · 2025Observational
- Development and validation of a nomogram for predicting the outcome of metabolic syndrome among people living with HIV after antiretroviral therapy in China.Frontiers in cellular and infection microbiology · 2025Article
- Low-Level Viremia as an Independent Risk Factor for Metabolic Syndrome in People Living with HIV Receiving Antiretroviral Therapy: A 6-Year Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study.Health science reports · 2024Article
- Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DFThe Lancet regional health. Western Pacific · 2024Article
- Changes in Body Mass Index Over Time in People With and Without HIV Infection.Open forum infectious diseases · 2024Article
- Metabolic syndrome among people living with HIV in Ethiopia: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2023Review
- Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.Infection & chemotherapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
objectivesWe investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all-cause mortality among Asian adults living with HIV.
methodsParticipants enrolled in a regional Asian HIV-infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing-risk regression models were used to investigate the association of MetS with all-cause mortality.
resultsAmong 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29-41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48-63) kg and 20.5 (18.4-22.9) kg/m
conclusionsWeight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI-based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.